Clinical trials: Headache Disorder
Cluster Headache
A Close Examination of Patient Experiences in Cluster Headache Clinical Research
Historically, participation in clinical studies is highly skewed towards particular demographic groups of people. This research will invite several participants to gather a wide range of information on clinical trial experiences…
- Trial name
- NCT05978258
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Migraine Disorders
An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention
This is a prospective, multi-center, unblinded study in patients with migraine (≥ 8 MMDs(monthly migraine days)/month) requiring preventive treatment.
- Trial name
- NCT06154070
- Testing
- DaxibotulinumtoxinA
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Ki Health Partners. LLC
Migraine
Consistency of Response With Rimegepant in Acute Treatment of Migraine
This is a non-interventional, prospective study that will enroll participants with migraine in the United Kingdom currently in use of rimegepant to acutely treat migraine attacks.
- Trial name
- CORRELATE-UK (NCT06898047)
- Testing
- Rimegepant for acute migraine treatment
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Pfizer
Migraine, Ketogenic Dieting
Th Effect of Ketogenic Metabolic Nutritional Pattern on High-frequency Episodic Migraine (EMIKETO)
The study aims to investigate the impact of 2 nutritional patterns on high-frequency episodic migraine. Subjects enrolled will be randomized in two arms: a) very-low-calorie-ketogenic-diet (VLCKD), b) hypocaloric balanced non…
- Conditions
- Migraine, Ketogenic Dieting, Weight Loss, Overweight
- Trial name
- EMIKETO (NCT04360148)
- Testing
- very-low-calorie-ketogenic-diet, hypocaloric-balanced-diet
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- New Penta SRL
Migraine
Continuous Treatment Study of Topiramate in Migraine Participants
The purpose of this study is to evaluate the safety and efficacy of topiramate in participants with migraine (type of severe headache that occurs periodically and is often associated with nausea, vomiting and constipation or…
- Trial name
- NCT01799590
- Testing
- Topiramate
- Where
- 25 sites in Japan
- Volunteers
- 296 people
- Sponsor
- Janssen Pharmaceutical K.K.
Migraine
Positron Emission Tomography (PET) Study of Brain Calcitonin Gene-Related Peptide (CGRP) Receptor Occupancy After Telcagepant Administration (MK-0974-067)
The purpose of this study is to determine the receptor occupancy (RO) associated with telcagepant (MK-0974) administration based on displacement of [11C]MK-4232 from the CGRP receptors in the brain using PET.
- Trial name
- NCT01315847
- Testing
- telcagepant, [11C]MK-4232
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Episodic Cluster Headache
Intranasal Civamide for Episodic Cluster Headache
This is a 49-day study to evaluate the effectiveness of Intranasal Civamide (Zucapsaicin) in the treatment of an episodic cluster headache period compared to placebo (medically inactive substance which does not contain any active…
- Trial name
- NCT00069082
- Testing
- Civamide (Zucapsaicin), Sodium Chloride
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- Winston Laboratories
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for the acute treatment of a single migraine attack.
- Trial name
- ACHIEVE I (NCT02828020)
- Testing
- Ubrogepant
- Where
- 90 sites in United States
- Volunteers
- 1,672 people
- Sponsor
- Allergan
Migraine
A Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-05180999 In Healthy Adults
PF-05180999 is a novel phosphodiesterase-2 (PDE2) inhibitor. The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of PF-05180999 administered twice daily over 14 days.
- Trial name
- NCT01981486
- Testing
- PF-05180999 Tablets
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Migraine
Safety and Tolerability of Frovatriptan to Prevention of Menstrually Associated Migraine (MAM) Headaches
In this open-label, multi-center study, patients were treated with frovatriptan for a maximum of 12 perimenstrual periods (PMPs).
- Trial name
- MAM (NCT01035983)
- Testing
- Frovatriptan 2.5 mg
- Where
- 5 sites in Germany, Hungary and 3 more
- Volunteers
- 550 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Migraine
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine
Primary Objective: To demonstrate the efficacy of fremanezumab administered as monthly and quarterly subcutaneous (sc) injections to adult Chinese participants with migraine.
- Trial name
- NCT05458011
- Testing
- Fremanezumab
- Where
- 29 sites in China
- Volunteers
- 365 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Migraine
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
A study to evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days in participants with episodic migraine.
- Trial name
- NCT01952574
- Testing
- Erenumab, Erenumab PFS, Erenumab AI/Pen
- Where
- 66 sites in United States, Canada and 5 more
- Volunteers
- 483 people
- Sponsor
- Amgen
Chronic Cluster Headache
A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)
The main goal of this trial is to inform about long-term safety and tolerability of eptinezumab in participants with chronic cluster headache.
- Trial name
- CHRONICLE (NCT05064397)
- Testing
- Eptinezumab
- Where
- 31 sites in United States, Denmark and 7 more
- Volunteers
- 131 people
- Sponsor
- H. Lundbeck A/S
Chronic Cluster Headache
Prevention and Acute Treatment of Chronic Cluster Headache Compared to Standard of Care
Subjects enrolled into this 10 week study will for the first two weeks document the number of cluster headaches and the means of treating (medication) of these attacks. Subjects will then be randomized to into either two groups.
- Trial name
- NCT01701245
- Testing
- GammaCore
- Where
- 10 sites in Belgium, Germany and 2 more
- Volunteers
- 97 people
- Sponsor
- ElectroCore INC
Migraine Without Aura, Migraine With Aura
Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study
Evaluation of headache response at 2 hours for active treated attacks for increasing dose.
- Trial name
- NCT01859481
- Testing
- Eletriptan HBr 40 mg, Eletriptan HBr 80 mg
- Where
- 148 sites in Belgium, Czechia and 12 more
- Volunteers
- 971 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.
- Trial name
- ACHIEVE II (NCT02867709)
- Testing
- Ubrogepant
- Where
- 109 sites in United States
- Volunteers
- 1,686 people
- Sponsor
- Allergan
Migraine Headache
A Study in Migraine Prevention
The primary objective of this study is to measure the change in frequency of migraine attacks per 28 days in migraine patients being treated orally with LY2300559 for 12 weeks.
- Trial name
- NCT01184508
- Testing
- LY2300559
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 87 people
- Sponsor
- Eli Lilly and Company
Migraine Disorders
Treximet ™ Pharmacy Budget Impact Model Database Validation Study
The purpose of this retrospective claims database study was to compare the change in migraine-related prescription (i.e. NSAIDs, Opioids, Ergots) utilization among migraine suffers following initiation of Treximet ™…
- Trial name
- NCT01332500
- Testing
- Sumatriptan/Naproxen combination, other oral triptans
- Volunteers
- 61,737 people
- Sponsor
- GlaxoSmithKline
Migraine
A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age
The primary objective of the study is to evaluate the effectiveness of fremanezumab as compared to placebo for the preventive treatment of chronic migraine (CM).
- Trial name
- NCT04464707
- Testing
- Fremanezumab
- Where
- 89 sites in United States, Canada and 7 more
- Volunteers
- 292 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Migraine Disorders
A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine
This open-label study will assess the long-term efficacy, safety, and tolerability of onabotulinumtoxinA administered for prophylaxis of headaches in patients with chronic migraine.
- Trial name
- NCT01516892
- Testing
- onabotulinumtoxinA
- Where
- 32 sites in United States, Australia and 1 more
- Volunteers
- 716 people
- Sponsor
- Allergan